Author contributions: P.B.: conception and design, collection and assembly of data, data analysis and interpretation, and manuscript writing; B.O.: collection, assembly, and analysis of confocal data; L.F.:statistical analysis; D.L. and G.B.: GBM provision; G.P.: conception and design, data analysis and interpretation, manuscript writing, and final approval of manuscript.
Cancer Stem Cells
Article first published online: 24 APR 2013
Copyright © 2013 AlphaMed Press
Volume 31, Issue 5, pages 857–869, May 2013
How to Cite
Brescia, P., Ortensi, B., Fornasari, L., Levi, D., Broggi, G. and Pelicci, G. (2013), CD133 Is Essential for Glioblastoma Stem Cell Maintenance. STEM CELLS, 31: 857–869. doi: 10.1002/stem.1317
Disclosure of potential conflicts of interest is found at the end of this article.
First published online in STEM CELLSEXPRESS January 10, 2013.
- Issue published online: 24 APR 2013
- Article first published online: 24 APR 2013
- Accepted manuscript online: 10 JAN 2013 11:27PM EST
- Manuscript Accepted: 13 DEC 2012
- Manuscript Received: 12 APR 2012
- Foundation Umberto Veronesi (FUV)
- Ministry of Health
- Cancer stem cell;
The role of the cell surface CD133 as a cancer stem cell marker in glioblastoma (GBM) has been widely investigated, since it identifies cells that are able to initiate neurosphere growth and form heterogeneous tumors when transplanted in immune-compromised mice. However, evidences of CD133-negative cells exhibiting similar properties have also been reported. Moreover, the functional role of CD133 in cancer stem/progenitor cells remains poorly understood. We studied the biological effects of CD133 downregulation in GBM patient-derived neurospheres. Our results indicate that there is not a hierarchical relation between CD133-positive and CD133-negative cells composing the neurospheres. Indeed, CD133 appears in an interconvertible state, changing its subcellular localization between the cytoplasm and the plasmamembrane of neurosphere cells. Silencing of CD133 in human GBM neurospheres using lentivirus-mediated short hairpin RNA impairs the self-renewal and tumorigenic capacity of neurosphere cells. These results imply that CD133 could be used as a therapeutic target in GBMs. STEM CELLS 2013;31:857–869